If you invest in the stock market, you must know the Anthem BioSciences share price targets for 2026, 2027, 2028, 2029, and 2030. Here, you will get detailed information regarding all your queries, such as its fundamentals, shareholdings, financial performance, future predictions, and more.
About Anthem BioSciences Ltd
Anthem BioSciences is a top biotech company in India that helps make important products like medicines, vitamins, and health supplements. It works with global pharmaceutical and life sciences companies to develop and manufacture high-quality drugs, enzymes, and other biotech solutions. Anthem uses advanced research and modern labs to create safe and effective products for healthcare, nutrition, and wellness. Its services include custom pharmaceutical manufacturing, contract research, and biotech product development, making it a trusted partner in the pharmaceutical and biotechnology industry. Many big healthcare brands rely on Anthem BioSciences for their R&D and large-scale production needs.
Fundamental Analysis of Anthem BioSciences
| Market Cap. | ₹42,534 Cr. |
| ROE | 23% |
| ROCE | 30.7% |
| P/E | 84.0 |
| P/B | 17.62 |
| Dividend Yield | 0% |
| Book Value | ₹42.92 |
| Face Value | ₹2 |
| 52-Week High | ₹770 |
| 52-Week Low | ₹701.90 |
Anthem BioSciences Share Price Target 2026
After analysing past price trends and market performance, it is estimated that the Anthem BioSciences stock price could reach a minimum of ₹790 and potentially achieve a maximum target of ₹830 in the year 2026.
| Year 2026 | Target Price |
|---|---|
| Minimum Price | ₹790 |
| Maximum Price | ₹830 |
Anthem BioSciences Share Price Target 2027
After analysing past price trends and market performance, it is estimated that the Anthem BioSciences stock price could reach a minimum of ₹840 and potentially achieve a maximum target of ₹890 in the year 2027.
| Year 2027 | Target Price |
|---|---|
| Minimum Price | ₹840 |
| Maximum Price | ₹890 |
Anthem BioSciences Share Price Target 2028
After analysing past price trends and market performance, it is estimated that the Anthem BioSciences stock price could reach a minimum of ₹900 and potentially achieve a maximum target of ₹950 in the year 2028.
| Year 2028 | Target Price |
|---|---|
| Minimum Price | ₹900 |
| Maximum Price | ₹950 |
Anthem BioSciences Share Price Target 2029
After analysing past price trends and market performance, it is estimated that the Anthem BioSciences stock price could reach a minimum of ₹960 and potentially achieve a maximum target of ₹1010 in the year 2029.
| Year 2029 | Target Price |
|---|---|
| Minimum Price | ₹960 |
| Maximum Price | ₹1010 |
Anthem BioSciences Share Price Target 2030
After analysing past price trends and market performance, it is estimated that the Anthem BioSciences stock price could reach a minimum of ₹1020 and potentially achieve a maximum target of ₹1080 in the year 2030.
| Year 2030 | Target Price |
|---|---|
| Minimum Price | ₹1020 |
| Maximum Price | ₹1080 |
Shareholding Pattern of Anthem BioSciences
| Retail & Others | 20.46% |
| Promoters | 74.69% |
| Foreign Institutions | 1.50% |
| Mutual Funds | 2.21% |
| Other Domestic Institutions | 1.14% |
Should You Invest in Anthem BioSciences Stock?
| Year | Target Price (₹) |
|---|---|
| 2026 | 790–830 |
| 2027 | 840–890 |
| 2028 | 900–950 |
| 2029 | 960–1010 |
| 2030 | 1020–1080 |
Whether you should invest or not, it depends on the many factors. Let us know the risk and opportunities to invest in Anthem BioSciences stock.
Opportunities
- Anthem BioSciences works in the fast-growing biotech and pharma research sector, which has strong long-term growth potential.
- The company offers contract research and manufacturing (CRAMS) services, a popular and rising segment in the healthcare industry.
- It focuses on new drug discovery and formulation development, which can lead to future high profits.
- Anthem serves both domestic and international clients, helping it gain global revenue exposure.
- The company benefits from India’s low-cost, high-skill research ecosystem, making its services competitive and profitable.
Risks
- Anthem BioSciences is not a listed company yet, so it’s hard to track real-time performance and financial updates.
- The biotech industry has long research cycles, which can delay profits and affect stock value.
- Business depends heavily on regulatory approvals from global health agencies, which can cause project delays.
- Any failure in drug trials or research projects may lead to big financial losses.
- Anthem faces strong competition from large pharma and research companies, which can limit market share and pricing power.
Key Competitors of Anthem BioSciences
Key competitors or peer companies of Anthem BioSciences are Cipla, Dr. Reddy’s Laboratories, Divi’s Laboratories, Biocon, Laurus Labs, Piramal Pharma Solutions, Glenmark Life Sciences, Syngene International, Jubilant Biosys, Aurobindo Pharma, GVK BioSciences, Sun Pharma, Lupin Limited, Zydus Lifesciences, and Strides Pharma Science.
Disclaimer: All the information provided in this article is for educational purposes only. DateUpdateGo always advises seeking guidance from a certified financial advisor before making any investment-related decisions.
